<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03804463</url>
  </required_header>
  <id_info>
    <org_study_id>2017PS017K</org_study_id>
    <nct_id>NCT03804463</nct_id>
  </id_info>
  <brief_title>The Multicentic Trial in Fertility-sparing Treatment and Ovarian Preservation Management for Early Endometrial Cancer</brief_title>
  <official_title>The Randomized Multicentic Prospective Controlled Trial in Fertility-sparing Treatment and Ovarian Preservation Management for Early Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Min Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shengjing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through multicenter, prospective, randomized, controlled clinical studies comparing different
      treatment options (fertility-sparing surgery and ovarian preservation surgery and radical
      surgery)therapeutic efficacy, safety and quality of life of patients, exploration of the best
      strategies and risks for the treatment of early endometrial cancer, and promotion and
      application.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients eligible for enrollment are selected and divided into three groups randomly,
      including fertility group,ovarian preservation group and endometrial cancer radical surgery
      group. Take interventions including fertility preservation surgery,ovarian preservation
      surgery and endometrial cancer radical surgery for patients in different groups respectively.
      Compare therapeutic efficacy, safety and quality of life of patients to evaluate three
      treatment and explore the best treatment for clinical application.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total survival Time</measure>
    <time_frame>6 months</time_frame>
    <description>calculate the time from patients enter the group to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change of Ovarian volume</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>measure the ovarian volume dynamically by ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of endocrine function evaluation</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>measure the endocrine function(hormone level) dynamically by blood detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>calculate the time from patients enter the group to tumor progression</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>radical surgery group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endometrial cancer radical surgery to be administered in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fertility preservation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fertility-sparing surgery to be administered in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ovarian preservation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ovarian preservation surgery to be administered in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endometrial cancer radical surgery</intervention_name>
    <description>Take hysterectomy and bilateral adnexectomy.</description>
    <arm_group_label>radical surgery group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fertility-sparing surgery</intervention_name>
    <description>Take endometrectomy , preserve uterus and bilateral ovaries.</description>
    <arm_group_label>fertility preservation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ovarian preservation surgery</intervention_name>
    <description>Take hysterectomy,preserve bilateral ovaries.</description>
    <arm_group_label>ovarian preservation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Premenopausal women, age â‰¤ 50 years

          2. Surgical curettage / hysteroscopic pathology confirmed, endometrioid adenocarcinoma
             G1/G2 (including well-differentiated, high-medium and middle-differentiation);

          3. Clinical consideration of IA (&lt;1/2 muscle infiltration);

          4. First-time treatment

          5. The subject (or his legal representative) must understand the nature of the study and
             sign an informed consent form.

        Exclusion Criteria:

          1. At the same time participate in other clinical trials;

          2. Can not tolerate surgery;

          3. Ovarian suspicious metastasis;

          4. Have a family history of ovarian cancer;

          5. Incorporate other malignant tumors;

          6. Preoperative CA125 abnormal persons
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Wang, PHD.</last_name>
    <role>Study Director</role>
    <affiliation>Shengjing Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Wang, PHD.</last_name>
    <phone>18940251222</phone>
    <email>wm21st@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>YiSi Liu</last_name>
    <phone>18640138683</phone>
    <email>liuyisi91@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shengjing Hospitaol of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Min Wang, PHD</last_name>
      <phone>18940251222</phone>
      <email>wm21st@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2019</study_first_posted>
  <last_update_submitted>January 14, 2019</last_update_submitted>
  <last_update_submitted_qc>January 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shengjing Hospital</investigator_affiliation>
    <investigator_full_name>Min Wang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Preservation of fertility surger</keyword>
  <keyword>ovarian preservation</keyword>
  <keyword>endometrial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

